• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inmune Bio Inc (NQ: INMB )

    5.445 -0.275 (-4.81%)
    Streaming Delayed Price Updated: 3:53 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 131,963
    Open 5.670
    Bid (Size) 5.420 (7)
    Ask (Size) 5.470 (7)
    Prev. Close 5.720
    Today's Range 5.420 - 5.670
    52wk Range 4.780 - 14.74
    Shares Outstanding 17,703,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
    From INmune Bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -51.47%
    -51.47%
    1 Month
    +7.19%
    +7.19%
    3 Month
    -19.09%
    -19.09%
    6 Month
    -52.07%
    -52.07%
    1 Year
    -20.51%
    -20.51%

    More News

    Read More
    INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Announces $13.0 Million Registered Direct Offering
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
    From INmune Bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    INmune Bio Inc. to Join Russell 3000® Index
    From INmune Bio, Inc.
    Via GlobeNewswire
    INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
    From INmune Bio, Inc.
    Via GlobeNewswire
    INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
    From INmune Bio, Inc.
    Via GlobeNewswire
    INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.